Here, we build upon these results by focusing on the other pathological hallmark of AD, tau, and evaluate PDDC’s potential to attenuate tau propagation and disease progression in PS19 tau transgenic mice as well as in an AAV-mediated human tau propagation model. Here, MAPT is linked to Alzheimer disease.